World Lifestyler
  • Art & Culture
    • Architecture
    • Art & Exhibitions
    • Books
    • Design
    • Film & Music
  • Competitions
    • Dining Experiences
    • Hotel Stays
    • Luxury Experiences
    • Product Giveaways
    • Reader Exclusives
    • Travel Giveaways
  • Food & Drink
    • Chefs
    • Coffee Culture
    • Food Destinations
    • Recipes
    • Restaurants
    • Wine & Spirits
  • Lifestyle
    • Design
    • Fashion
    • Health & Wellbeing
    • Homes & Property
    • Love & Romance
  • People
    • Creatives
    • Entrepreneurs
    • Icons
    • Interviews
    • Profiles
    • Rising Talent
  • Travel
    • Adventure & Experience Travel
    • City Guides
    • Destinations
    • Hotels
    • Secret Spots
    • Travel Trends
  • Art & Culture
    • Architecture
    • Art & Exhibitions
    • Books
    • Design
    • Film & Music
  • Competitions
    • Dining Experiences
    • Hotel Stays
    • Luxury Experiences
    • Product Giveaways
    • Reader Exclusives
    • Travel Giveaways
  • Food & Drink
    • Chefs
    • Coffee Culture
    • Food Destinations
    • Recipes
    • Restaurants
    • Wine & Spirits
  • Lifestyle
    • Design
    • Fashion
    • Health & Wellbeing
    • Homes & Property
    • Love & Romance
  • People
    • Creatives
    • Entrepreneurs
    • Icons
    • Interviews
    • Profiles
    • Rising Talent
  • Travel
    • Adventure & Experience Travel
    • City Guides
    • Destinations
    • Hotels
    • Secret Spots
    • Travel Trends
No Result
View All Result
WORLD LIFESTYLER
No Result
View All Result
Home Press Releases Press Releases - Lifestyle

Innogen to Present Phase IIb ENLIGHT Study Results for Efsubaglutide Alfa at the 2026 ADA Scientific Sessions

Cision PR Newswire by Cision PR Newswire
May 29, 2026
in Press Releases - Lifestyle
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

SHANGHAI, May 29, 2026 /PRNewswire/ — Innogen (HKEX: 2591), a biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for metabolic diseases, today announced that new clinical data from the Phase IIb ENLIGHT study of Efsubaglutide alfa in overweight and obesity will be presented at the 2026 American Diabetes Association (ADA) Scientific Sessions, to be held from June 5 to 8, 2026, in New Orleans, Louisiana, USA.

Presentation Details

Poster Title: Efsubaglutide Alfa in Overweight or Obesity: Phase IIb ENLIGHT Study

Abstract Number: 2636-P

Presentation Time: June 8, 2026, 12:30 PM (Central Time)

Presenter: Qinghua Wang, Ph.D., Founder, Chairman and Chief Executive Officer of Innogen

Innogen’s proprietary Efsubaglutide α met the primary endpoint of the Phase IIb ENLIGHT study conducted in Chinese overweight and obese adults. This randomized, double-blind, placebo-controlled, multicenter study enrolled 200 overweight and obese adults without diabetes to evaluate the efficacy and safety of Efsubaglutide α at doses ranging from 5 to 20 mg for 18 weeks. Results showed that all dose groups experienced significant weight loss from baseline, superior to the placebo group, and the weight loss was positively correlated with the dose. During treatment, patients in the Efsubaglutide α group showed a continuous weight loss trend without a plateau.

The study employed a concise and aggressive dose titration protocol (incrementing every 2 weeks to reach the target dose of 20 mg within 6 weeks, covering both QW and Q2W dosing routes). Results showed that after 18 weeks of treatment including titration and maintenance, Efsubaglutide α significantly reduced the weight of participants, with reductions of 10.58% and 9.70% in the QW and Q2W groups, respectively. Meanwhile, the subjects’ waist circumference, visceral fat, and liver fat metabolism indicators all showed significant improvement. Notably, the weight loss was primarily due to fat rather than muscle, resulting in a significant increase in the muscle-to-fat ratio of 45.3%; furthermore, liver fat content decreased significantly by 46.9%. Regarding safety, no hypoglycemic events occurred during treatment, and gastrointestinal adverse reactions were mostly mild to moderate, transient, and self-limiting.

Dr. Wang Qinghua pointed out: The Phase IIb clinical trial results of Efsubaglutide α presented at this ADA Annual Meeting are very encouraging. As an innovative long-acting agonist originating from China, this drug, through its unique molecular structure design, combines potent weight loss with the efficacy of ‘fat reduction and muscle protection,’ possessing significant differentiated core advantages, good tolerability, and convenient administration. This set of high-quality clinical data fully demonstrates the broad prospects of Efsubaglutide α in the field of obesity treatment and provides strong scientific evidence for the upcoming Phase III clinical trial. We will go all out to accelerate subsequent research, promoting the early implementation of this original Chinese achievement to benefit patients both domestically and internationally.

Note: This content is for informational purposes only, not an advertisement, advice, or efficacy claim. Use prescription drugs only as directed by a physician.

About Innogen Pharmaceuticals
Founded in 2014, Innogen (HK.2591) focuses on innovative metabolic disease drugs, with fully proprietary pipelines covering T1D, obesity, MASH, and AD, supported by global IP and patent portfolios. Its core product, Efsubaglutide Alfa (a next-generation human-derived ultra-long-acting GLP-1 receptor agonist), is approved for type 2 diabetes in Chinese Mainland and Macau SAR, included in China’s National Reimbursement Drug List, and is under global development and registration. Learn more: www.innogenpharm.com.

Cision View original content:https://www.prnewswire.com/news-releases/innogen-to-present-phase-iib-enlight-study-results-for-efsubaglutide-alfa-at-the-2026-ada-scientific-sessions-302785669.html

SOURCE Innogen Pharmaceuticals

Cision PR Newswire

Cision PR Newswire

Related Posts

The One Where SHEGLAM Meets FRIENDS

October 26, 2026

Rapidus and HCLTech announce partnership for next-generation semiconductor technologies

October 26, 2026

Parloa’s Agent Management Platform now sold as an SAP Solution Extension for agentic customer interactions

October 26, 2026

Temu Partners with Spain’s Recyclia to Support Seller Extended Producer Responsibility

October 26, 2026

SUNON Brings AI, Nature and Human-Centered Design to ORGATEC 2026

October 26, 2026

Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma

October 26, 2026

Popular News

  • Agiloft Positioned as a Leader in Contract Lifecycle Management Platforms Report by Independent Research Firm

    0 shares
    Share 0 Tweet 0
  • EWTN News Expands Flagship Newscast to Next Generation of Catholics

    0 shares
    Share 0 Tweet 0
  • Wirex Now Powers Tokenized Stocks

    0 shares
    Share 0 Tweet 0
  • ETHOS SUPPORT APPOINTS NATHANAEL ROBBINS AS CHIEF OPERATING OFFICER TO ACCELERATE GLOBAL GROWTH

    0 shares
    Share 0 Tweet 0
  • UBE Capital Announces Closing of Senior Secured Upstream Facility and Launch of Inaugural Energy Credit Fund

    0 shares
    Share 0 Tweet 0

About & Contact

  • About Us
  • Branding Style Guide
  • Contact Us
  • Help Centre
  • Media Kit
  • Site Map

Explore Content

  • Events
  • Newsletter
  • Press Releases
  • Topics

Legal & Privacy

  • Advertiser & Partner Policy
  • Communications & Newsletter Policy
  • Contributor Agreement
  • Copyright Policy
  • Privacy Policy
  • Prohibited Content Policy
  • Terms of Service

Tiny Media Brands

  • Silicon Valleys Journal
  • The AI Journal
  • The City Banker
  • The Wall Street Banker
  • World Lifestyler

© 2025 World Lifestyler

No Result
View All Result
  • Home

© 2025 World Lifestyler